Embed Size (px)
Citation preview
Richard Aaron Hansen Personal:
University Address: Auburn University Harrison School of Pharmacy 2316 Walker Building Auburn, AL 36849-5506 Phone: (334) 844-8302 Email: [email protected]
Home Address: 1794 Covington Ridge #1302 Auburn, AL 36830 Cell: (334) 740-6741
Education: August 2003 Doctor of Philosophy University of Minnesota, Minneapolis, MN
Social, Administrative & Clinical Pharmacy May 1997 Bachelor of Science in Pharmacy University of Wisconsin, Madison, WI Licensures: 2019 – Present Registered Pharmacist, Alabama License Number: 20814 1997 – Present Registered Pharmacist, Wisconsin Department of Safety & Professional Services License Number: 12702-40 1999 – 2003 Registered Pharmacist, Minnesota (relocated) 1997 – 1999 Registered Pharmacist, Texas (relocated) Professional Experience: 2017 – Present Dean, Harrison School of Pharmacy, Auburn University 2010 – Present Gilliland Endowed Professor 2010 – 2017 Department Head; Health Outcomes Research and Policy, Harrison School of
Pharmacy, Auburn University 2012 – 2014 Chair Elect / Chair – Economic, Social, and Administrative Sciences Section
(ESAS) of the American Pharmacists Association Academy of Pharmacy Research and Science (APhA-APRS)
2008 – 2010 Associate Professor (with tenure); University of North Carolina at Chapel Hill, School of Pharmacy - Division of Pharmaceutical Outcomes and Policy
2003 – 2008 Assistant Professor; University of North Carolina at Chapel Hill, School of Pharmacy - Division of Pharmaceutical Outcomes and Policy
2000 – 2003 Research Assistant; University of Minnesota College of Pharmacy, Department of Pharmaceutical Care and Health Systems
1999 – 2003 Pharmacist; Cub Pharmacy, Minneapolis metro area 1999 – 2002 Teaching Assistant; University of Minnesota College of Pharmacy, Department
of Pharmaceutical Care and Health Systems Summer 2001 Summer Intern; Minnesota Mining and Manufacturing (3M) Health Care, Skin
Health Division, Health Economics Intern 1997 – 1999 Pharmacist; University of Texas Medical Branch, Galveston, TX Summer 1997 Pharmacy Intern; Walgreen’s Pharmacy, Milwaukee, WI
1996 – 1997 Pharmacy Intern; University of Wisconsin Hospitals and Clinics, Madison, WI
Summer 1996 Pharmacy Intern; Bellin Hospital, Green Bay, WI 1994 – 1996 Pharmacy Technician; University of Wisconsin Hospitals and Clinics,
Madison, WI
Honors: 2016 Auburn University Creative Research and Scholarship Award 2015 Harrison School of Pharmacy Faculty Research Excellence Award 2015 Outstanding Peer Reviewer – Annals of Internal Medicine and Journal of
Managed Care Pharmacy 2014 Harrison School of Pharmacy Faculty Research Excellence Award 2013 Appointed to Alabama Regional Care Organization Quality Assurance
Committee 2012 Harrison School of Pharmacy Faculty Research Excellence Award 2012 Named Fellow of the American Pharmacists Association 2012 Outstanding Peer Reviewer – Annals of Internal Medicine 2011 Harrison School of Pharmacy Faculty Research Excellence Award 2010 – present Sandra Kent Gilliland & David Louie Gilliland Endowed Professorship 2009 International Society for Pharmacoeconomics and Outcomes Research, Best Poster Presentation 2009 Outstanding Peer Reviewer – Annals of Internal Medicine 2008 – 2009 Top Peer Reviewer – Research in Social and Administrative Pharmacy 2006 – 2009 Clinical Scholar – University of North Carolina K12/KL2 program 2006 Outstanding Peer Reviewer – Journal of Managed Care Pharmacy 2004 – present Research Fellow – Cecil G. Sheps Center for Health Services Research 2003 American Association of Pharmaceutical Scientists (AAPS) Outstanding Presentation Award 2003 International Society for Pharmacoeconomics and Outcomes Research, Distinguished Service Award 2002 – 2003 Thompson’s MEDSTAT MarketScan Dissertation Support Program 2002 – 2003 American Foundation for Pharmaceutical Education (AFPE), Doctoral
Dissertation Fellow 2001 – 2002 Melendy Dissertation Scholarship – University of Minnesota 2001 – 2002 American Foundation for Pharmaceutical Education (AFPE), Doctoral
Dissertation Fellow
Publications: Peer-Reviewed Published or in Press Research Articles (most recent first) 1. Huo N, Chen L, Ulluh Mishuk A, Li C, Hansen RA, Harris I, Kiptanui Z, Wang Z, Dutcher SK, Qian J.
Generic levothyroxine initiation and substitution among Medicare and Medicaid populations: a new user cohort study. Endocrine. 2020 (epub ahead of print).
2. Gamston CE, Kirby AN, Hansen RA, Redden D, Whitley HP, Hanson C, Lloyd KB. Comparison of 3 risk factor-based screening tools for the identification of prediabetes. Journal of the American Pharmacist Association. 2019 (epub ahead of print).
3. Hohmann NS, Garza KB, Surry D, Hansen RA, Harris I, Kiptanui Z, Oguntimein O, Frost MM, Qian J. Healthcare provider opinions about generic drug educational newsletter: A pilot cross-sectional survey. Research in Social and Administrative Pharmacy. 2019 (Epub ahead of print).
4. Chou C, Hohmann NS, Hastings TJ, Li C, McDaniel CC, Maciejewski ML, Farley JF, Domino ME, Hansen
RA. How comfortable are primary care physicians and oncologists prescribing medications for comorbidities in patients with cancer? Research in Social and Administrative Pharmacy. 2019 (Epub ahead of print).
5. Gamston CE, Kirby AN, Hansen RA, Redden DT, Whitley HP, Hanson C, Lloyd KB. Description of a
pharmacist-led diabetes prevention service within an employer-based wellness program. Journal of the American Pharmacist Association. 2019; 59(5):736-41.
6. Lin YT, Lu TS, Hansen RA, Wang CC. Selective serotonin reuptake inhibitor use and risk of arrhythmia: a nationwide, population-based cohort study. Clinical Therapeutics. 2019; 41(6):1128-38.
7. Zhang Y, Rants’o TA, Jung D, Lopez E, Abbott K, Pondugula SR, McLendon L, Qian J, Hansen RA,
Calderon A. Screening for CYP3A4 inhibition and induction coupled to parallel artificial membrane permeability assay (PAMPA) for prediction of botanical-drug interactions: The case of açaí and maca. Phytomedicine. 2019 (epub ahead of print).
8. Jeminiwa R, Hohmann L, Qian J, Garza K, Hansen R, Fox BI. Impact of eHealth on medication adherence among patients with asthma: A systematic review and meta-analysis. Respiratory Medicine (in press).
9. Hohmann NS, Garza KB, Surry D, Hansen RA, Harris I, Kiptanui Z, Oguntimein O, Frost MM, Qian J. Communicating benefits and risks of generic drugs to consumers: Patient and caregiver opinions of two FDA-developed educational materials. Research in Social and Administrative Pharmacy. 2019; 15(12):1489-93.
10. Sonawane KB, Cheng N, Hansen RA. Serious Adverse Drug events reported to the FDA: Analysis of the
FDA Adverse Event Reporting System 2006-2014 Database. Journal of Managed Care and Specialty Pharmacy. 2018; 24(7):682-690.
11. Qian J, Mishuk AU, Hansen RA. Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs. Expert Opinion on Drug Safety. 2018; 17(8):753-756.
12. Hohmann N, Hansen RA, Garza KB, Harris I, Kiptanui Z, Qian J. Association between higher generic drug use and Medicare Part D prescription plan star ratings: an observational analysis. Value in Health. In press
13. Li C, Hansen RA, Chou C, Calderon AI, Qian J. Trends in botanical dietary supplement use among US adults by cancer status: The National Health and Nutrition Examination Survey, 1999 to 2014. Cancer. 2018; 124(6):1207-15.
14. Cheng N, Rahman MM, Alatawi Y, Qian J, Peissig PL, Berg RL, Page CD, Hansen RA. Mixed retrospective analyses of suicide and suicidal ideation for brand compared with generic central nervous system drugs. Drug Safety. 2018; 41(4):363-76.
15. Alatawi Y, Rahman MM, Cheng N, Qian J, Peissig PL, Berg RL, Page CD, Hansen RA. Brand vs. generic
adverse event reporting patterns: an authorized generic-controlled evaluation of cardiovascular medications. Journal of Clinical Pharmacy and Therapeutics. 2018; 43(3):327-35.
16. Hansen RA, Hohmann N, Maciejewski ML, Domino ME, Ray N, Mahendraratnam N, Farley JF. Continuity of medication management among adults with schizophrenia and comorbid cardiometabolic conditions. Journal of Pharmaceutical Health Services Research. 2018; 9(1):13-20.
17. Stirratt MJ, Curtis JR, Danila MI, Hansen RA, Miller MJ, Gakumo CA. Advancing the science and practice of medication adherence. Journal of General Internal Medicine. 2017 (epub ahead of print).
18. Rahman MM, Alatawi Y, Cheng N, Qian J, Peissig PL, Berg RL, Page DC, Hansen RA. Methodological
considerations for comparison of brand versus generic versus authorized generic adverse event reports in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Clinical Drug Investigation. 2017; 37(1):1143-52.
19. Howard J, Harris I, Kiptanui Z, Frank G, Hansen RA, Qian J. Influencers of generic drug utilization: a systematic review. Research in Social and Administrative Pharmacy (in press).
20. Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opinion in Drug Safety. 2017; 16(7):761-67.
21. Rahman MM, Alatawi Y, Cheng N, Qian J, Plotkina AV, Peissig PL, Berg RL, Page D, Hansen RA. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Epilepsy Research. 2017; 135:71-8.
22. Qian J, Hansen RA, Surry D, Howard J, Kiptanui Z, Harris I. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing. Pharmacoepidemiology and Drug Safety. 2017; 26(7):819-826.
23. Wittayanukorn S, Qian J, Westrick SC, Billor N, Johnson B, Hansen RA. Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or beta-blockers in older adults with breast cancer. American Journal of Clinical Oncology (epub ahead of print)
24. Sonawane Deshmukh KB, Qian J, Garza KB, Wright BM, Zeng P, Ganduglia Cazaban CM, Hansen RA. Healthcare costs associated with addition, titration, and switching antihypertensive medications after first-line treatment: results from a commercially insured sample. Journal of Managed Care and Specialty Pharmacy. 2017; 23(6):691-99.
25. Cheng N, Banerjee T, Qian J, Hansen RA. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011. Journal of the American Pharmacists Association. 2017; 57(3):341-48.
26. Rahman MM, Scalese MJ, Hansen RA. Dipeptidyl Peptidase-4 Inhibitor–associated risk of bleeding: an
evaluation of reported adverse events. Annals of Pharmacotherapy. 2017; 51(7):563-69.
27. Hansen RA, Qian J, Berg RL, Linneman JG, Seoane-Vazquez E, Dutcher S, Raofi S, Page CD, Peissig PL. Comparison of generic-to-brand switchback patterns for generic and authorized generic drugs. Pharmacotherapy. 2017; 37(4):429-37.
28. Hansen RA, Qian J, Berg RL, Linneman JG, Seoane-Vazquez E, Dutcher S, Raofi S, Page CD, Peissig PL. Comparison of outcomes following a switch from a brand to an authorized vs. independent generic drug. Clinical Pharmacology and Therapeutics. 2018; 103(2):310-17.
29. Farley JF, Hansen RA, Domino ML, Borse M, Ray N, Maciejewski ML. Continuity of medication management in Medicaid patients with chronic comorbid conditions: an examination by mental health status. General Hospital Psychiatry. 2017; 45:25-31.
30. Qian J, Wittayanukorn S, Hansen RA. Patterns of psychiatric emergency department utilization among community-dwelling Medicare beneficiaries under 65. Psychological Services 2017; 14(3):387-96.
31. Sonawane Deshmukh KB, Qian J, Garza KB, Wright BM, Zeng P, Ganduglia Cazaban CM, Hansen RA. Achieving adherence after first-line antihypertensive treatment: Should fixed-dose combinations receive priority? Journal of Clinical Hypertension 2016; 18(9):934-41.
32. Rodriguez-Monguio R, Seoane-Vazquez E, Hansen RA. Interchangeability, safety and efficacy of modified release drug formulations in the US: the case of opioid and other nervous system drugs. Clinical Drug Investigation 2016; 36(4):281-292.
33. Hansen RA, Williamson M, Stevenson L, Davis BR, Evans RL. Disseminating comparative effectiveness research through community-based experiential learning. American Journal of Pharmacy Education. 2017; 81(1):9.
34. Qian J, Wittayanukorn S, McGuffey G, Hansen RA. Factors associated with psychotropic prescriptions, psychiatric hospitalization, and spending among Medicare beneficiaries under 65. Disability and Health Journal 2015; 8(3):424-33.
35. Wittayanukorn S, Qian J, Johnson B, Hansen RA. Cardiotoxicity in targeted therapy for breast cancer: a study of the FDA Adverse Event Reporting System (FAERS). Journal of Oncology Pharmacy Practice. 2017; 23(2):93-102.
36. Huang WT, Erickson SR, Hansen RA, Wu CH. The association between regular use of aspirin and the risk of prostate cancer: results from the National Health Interview Survey. Medicine 2016; 95(25):e3909
37. Hansen RA, Khodneva Y, Glasser SP, Qian J, Redmond N, Safford MM. Antidepressant medication use and its association with cardiovascular disease and all-cause mortality in the Reasons for Geographic and Ethnic Differences in Stroke (REGARDS) Study. Annals of Pharmacotherapy 2016; 50(4):253-61.
38. Desai R, Thaler K, Mahlknecht P, Gartlehner G, Mcdonagh M, Mesgarpour B, Mazinanian A, Glechner A, Gopalakrishnan C, Hansen RA. Comparative risk of harm associated with the use of targeted immunomodulators. Arthritis Care and Research 2016; 68(8):1078-88.
39. Sonawane KB, Qian J, Garza KB, Wright BM, Zeng P, Ganduglia Cazaban CM, Hansen RA. Patterns of
treatment modifications among newly treated hypertensive patients: Does choice of modification strategy affect likelihood of treatment discontinuation? Journal of Hypertension 2016; 34(3):548-57.
40. Garza KB, Owensby J, Braxton-Lloyd K, Wood EA, Hansen RA. Pilot study to test the effectiveness of different financial incentives on medication adherence. Annals of Pharmacotherapy 2016; 50(1):32-8.
41. Wittayanukorn S, Qian J, Westrick S, Billor N, Johnson BS, Hansen RA. Treatment patterns among breast cancer patients in the United States using two National surveys on visits to physicians' offices and hospital outpatient departments. Research in Social and Administrative Pharmacy 2015; 11(5):708-20.
42. Hansen RA, Voils CI, Farley JF, Powers BJ, Sanders LL, Sleath B, Maciejewski ML. Prescriber continuity and medication adherence for complex patients. Annals of Pharmacotherapy 2015; 49(3):293-302.
43. Sonawane K, Qian J, Hansen RA. Utilization patterns of antihypertensive drugs among the chronic kidney disease population in the US: A cross-sectional analysis of the National Health and Nutrition Examination Survey. Clinical Therapeutics 2015; 1(37):188-96.
44. Hansen RA, Zeng P, Ryan P, Gao J, Sonawane K, Teeter B, Westrich K, Dubois RW. Exploration of heterogeneity in distributed research network drug safety analyses. Research Synthesis Methods 2014; 5:352-370.
45. Mulherin DW, Hutchison AM, Thomas GJ, Hansen RA, Childress DT. Concordance of the SHEA-IDSA severity classification for Clotridium difficile infection and the ATLAS bedside scoring system in hospitalized adult patients. Infection 2014; 42(6):999-1005.
46. Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley JF. Predictors of treatment initiation with tumor necrosis-α inhibitors in patients with rheumatoid arthritis. Journal of Managed Care and Specialty Pharmacy 2014; 20(11):1110-20.
47. Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley JF. TNF-alpha inhibitor treatment and risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. Journal of Rheumatology 2014; 41(11):2129-36.
48. Nussbaumer B, Morgan LC, Reichenpfader U, Greenblatt A, Hansen RA, Van Noord M, Lux L, Gaynes BN, Gartlehner G. Comparative efficacy and risk of harms of immediate- vs. extended-release second generation antidepressants – a systematic review with network meta-analysis. CNS Drugs 2014; 28(8):699-712.
49. Gaynes BN, Lloyd SW, Lux L, Gartlehner G, Hansen RA, Brode S, Jonas D, Swinson-Evans, T, Viswanathan M, Lohr K. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. Journal of Clinical Psychiatry 2014; 75(5):477-89.
50. Wittayanukorn S, Qian J, Hanasen RA. Prevalence of depressive symptoms and predictors of treatment among US adults from 2005 to 2010. General Hospital Psychiatry 2014; 36(3):330-6.
51. Maciejewski ML, Powers BJ, Sanders LL, Farley JF, Hansen RA, Sleath B, Voils CI. The intersection of patient complexity, prescriber continuity, and acute care utilization. Journal of General Internal Medicine 2014; 29(4):594-601.
52. Reichenpfader U, Gartlehner G, Greenblatt A, Morgan LC, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder – results from a systematic review with network meta-analysis. Drug Safety 2014; 37(1):19-31.
53. Hansen RA, Gray MD, Fox BI, Hollingsworth JC, Gao J, Hollingsworth ML, Carpenter DM. Expert panel
assessment of acute liver injury identification in observational data. Research in Social and Administrative Pharmacy 2014; 10(1):156-67.
54. Watson LC, Esserman D, Ivey JL, Hansen RA, Lewis CL, Weinberger M, Roth MT. Enhancing Quality in Psychiatry Using Pharmacists (EQUIPP). American Journal of Geriatric Psychiatry 2014; 22(9):884-8.
55. Hansen RA, Gray MD, Fox BI, Hollingsworth JC, Gao J, Zeng P. How well do various health outcome definitions identify appropriate cases in observational studies. Drug Safety 2013; 36(supplement 1):S27-S32.
56. Hansen RA, Farley JF, Maciejewski ML, Ye X, Qian C, Powers BJ. Real-world utilization patterns and
outcomes of colesevelam HCL in the GE electronic medical record. BMC Endocrine Disorders 2013; 13(1):24.
57. Fox BI, Hollingsworth JC, Gray MD, Hollingsworth ML, Gao J, Hansen RA. Developing an expert panel
process to refine health outcome definitions in observational data. Journal of Biomedical Informatics 2013; 46(5):795-804.
58. Desai RJ, Williams CE, Greene SB, Pierson S, Hansen RA. Anticoagulant medication errors in nursing homes: characteristics, causes, outcomes, and association with patient harm. Journal of Healthcare Risk Management 2013; 33(1):33-43.
59. Desai RJ, Williams CE, Greene SB, Pierson S, Caprio AJ, Hansen RA. Exploratory evaluation of medication classes most commonly involved in nursing home errors. Journal of the American Medical Directors Association 2013; 14(6):403-8.
60. Desai RJ, Williams CE, Greene SB, Pierson S, Caprio AJ, Hansen RA. Analgesic medication errors in North Carolina nursing homes. Journal of Pain and Palliative Care Pharmacotherapy 2013; 27(2):125-31.
61. Wittayanukorn S, Westrick SC, Hansen RA, Billor N, Braxton-Lloyd K, Fox BI, Garza KB. Evaluation of
Medication Therapy Management (MTM) services for patients with cardiovascular disease in a self-insured employer health plan. Journal of Managed Care Pharmacy 2013; 19(5) 385-95.
62. Ellis AR, Dustezina SB, Hansen RA, Gaynes BN, Farley JF, Stürmer T. Confounding control in a non-experimental study of STAR*D data: Logistic regression balanced covariates better than boosted CART. Annals of Epidemiology 2013; 23(4):204-9.
63. Ellis AR, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, Sturmer T. Investigating differences in
treatment effect estimates between propensity score matching and weighting: A demonstration using STAR*D trial data. Pharmacoepidemiology and Drug Safety 2013; 22(2)138-44.
64. Hansen RA, Esserman DA, Roth MT, Lewis C, Ivey Burkhart J, Weinberger M, Watson LC. Medication
adherence measurement with the Medometer visual tool: comparison with other measures in a geriatric psychiatry pilot study. Journal of the American Pharmacists Association 2013; 53(2):198-205.
65. Dusetzina SB, Weinberger M, Gaynes BN, Farley JF, Sleath B, Hansen RA. Prevalence of bipolar disorder
and psychotropic drug therapy among privately insured children and adolescents. Pharmacotherapy 2012; 32(12):1085-1094.
66. Desai RJ, Hansen RA, Rao JK, Wilkins TM, Harden EA, Yuen A, Jonas DE, Roubey R, Jonas B,
Gartlehner G, Lux L, Donahue DE. Mixed treatment comparison of the treatment discontinuations of biologic disease-modifying antirheumatic drugs in adults with rheumatoid arthritis. Pharmacotherapy 2012; 46(11):1491-505.
67. Dusetzina SB, Farley JF, Weinberger M, Gaynes BN, Sleath B, Hansen RA. Treatment use and costs
among privately-insured youth with bipolar diagnoses. Psychiatric Services 2012; 63:1019-25.
68. Thaler KJ, Morgan LC, Van Noord M, Gaynes BN, Hansen RA, Lux LJ, Krebs EE, Lohr KN, Gartlehner G. Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. Depression and Anxiety 2012; 29:495-505.
69. Aljadhey H, Tu W, Hansen RA, Blalock SJ, Brater DC, Murray MD. Comparative effects of non-steroidal
anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. BMC Cardiovascular Disorders 2012; 12:93
70. Gartlehner G, Thaler K, Hill S, Hansen RA. How should primary care doctors select which antidepressants
to administer? Current Psychiatry Reports 2012; 14(4):360-9.
71. Jones KM, Blumenthal DK, Burke JM, Condren M, Hansen RA, Holiday-Goodman M, Peterson CD. Survey of interprofessional education in IPPEs at US colleges of pharmacy. American Journal of Pharmacy Education 2012; 76(5):1-9.
72. Farley JF, Hansen RA, Yu-Isenberg KS, Maciejewski ML. Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions. The Primary Care Companion for CNS Disorders 2012; 14(3):e1-e8.
73. Hansen RA, Farley JF, Yu-Isenberg K, Maciejewski ML. Adherence to antipsychotic and cardiometabolic
medication: association with healthcare utilization and cost. Psychiatric Services 2012; 63(9):920-8.
74. Katz AJ, Dusetzina SB, Farley JF, Ellis AR, Gaynes BN, Castillo WC, Sturmer T, Hansen RA. Adverse events following antidepressant switch: the influence of patient experiences during initial treatment with citalopram. Pharmacotherapy 2012; 32(3):234-43
75. Hansen RA, Dusetzina SB, Ellis AR, Stürmer T, Farley JF, Gaynes BN. Risk of adverse events in treatment
resistant depression: propensity-score matched comparison of antidepressant augment and switch strategies. General Hospital Psychiatry. 2012; 34(2):192-200.
76. Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, Stürmer T. Treating depression after initial treatment failure: A Propensity-Score Matched Comparison of STAR*D switch and augmenting strategies. Journal of Clinical Psychopharmacology 2012; 32(1):114-19.
77. Crockett SD, Hansen RA, Sturmer T, Schectman R, Darter J, Sandler RS, Kappelman MD. Statins are
associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflammatory Bowel Diseases 2012 Jun; 18(6):1048-56.
78. Gartlehner G, Hansen RA, Morgan L, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN. Comparative benefits and harms of second-generation antidepressants for the treatment of major depressive disorder. Annals of Internal Medicine 2011;155(11):772-85.
79. Desai R, Williams CE, Greene SB, Pierson S, Hansen RA. Medication errors during patient transitions into
nursing homes: characteristics and association with patient harm. American Journal of Geriatric Pharmacotherapy. 2011; 9(6):413-22.
80. Dusetzina SB, Gaynes BN, Weinberger M, Farley JF, Sleath B, Hansen RA. Receipt of guideline-
concordant pharmacotherapy among children with new diagnoses of bipolar disorder. Psychiatric Services 2011; 62(12):1443-9.
81. Greene SB, Williams CE, Pierson S, Hansen RA and Carey TS. Online Medication Error Graphic Reports:
A Pilot in North Carolina Nursing Homes. Journal of Patient Safety 2011; 7(2):92-98. 82. Farley JF, Wang CC, Hansen RA, Voils CI, Maciejewski ML. Continuity of antipsychotic medication
management for Medicaid patients with schizophrenia. Psychiatric Services 2011; 62(7):747-52. 83. Gaynes BN, Farley JF, Dusetzina SB, Ellis AR, Hansen RA, Miller WC, Sturmer T. Does the presence of
accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression. Depression and Anxiety 2011; 28(11):989-98.
84. Hansen NL, Chandiramani D, Morse MA, Wei D, Hedrick NE, Hansen RA. Incidence and predictors of
cetuximab hypersensitivity reactions in a North Carolina academic medical center. Journal of Oncology Pharmacy Practice 2011; 17(2):125-30.
85. Hansen RA, Chen SY, Gaynes BN, Maciejewski ML. Relationship of pharmaceutical promotion to
antidepressant switching and adherence: a retrospective cohort study. Psychiatric Services 2010; 61(12):1232-38.
86. Hansen RA, Cornell PY, Ryan PB, Williams CE, Pierson S, Greene SB. Patterns in nursing home medication errors: disproportionality analysis as a novel method to identify quality improvement opportunities. Pharmacoepidemiology and Drug Safety 2010; 19(9):1087-94.
87. Hansen RA, Farley JF, Droege M, Maciejewski ML. A retrospective cohort study of economic outcomes
and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the united states from 2003 to 2005. Clinical Therapeutics 2010; 32(7):1308-19.
88. Aljadey H, Tu W, Hansen RA, Blalock S, Brater DC, Murray MD. Risk of hyperkalemia associated with
selective COX-2 inhibitors. Pharmacoepidemiology and Drug Safety 2010; 19(11):1194-98. 89. Crespin DJ, Modi AV, Wei D, Williams CE, Greene SB, Pierson S, Hansen RA. Repeat medication errors
in nursing homes: contributing factors and their association with patient harm. American Journal of Geriatric Pharmacotherapy 2010. 8(3):258-70.
90. Chen SY, Hansen RA, Gaynes BN, Farley JF, Morrisey JP, Maciejewski ML. Guideline-concordant
antidepressant use among patients with major depressive disorder. General Hospital Psychiatry 2010; 32:360-7.
91. Hansen RA, Dusetzina SB, Dominik RC, Gaynes BN. Prescription refill records as a screening tool to
identify antidepressant non-adherence. Pharmacoepidemiology and Drug Safety 2010; 19(1):33-7. 92. Maciejewski ML, Farley JF, Hansen RA, Wei D, Harman JS. Part D plan enrollment by uninsured
Medicare beneficiaries. Medical Care 2010; 48:183-86. 93. Chen SY, Hansen RA, Farley JF, Gaynes BN, Morrisey JP, Maciejewski ML. Provider specialty and
follow-up visits for patients with major depressive disorder treated with antidepressants. Psychiatric Services 2010; 61(1):81-5.
94. Greene SB, Williams CE, Pierson S, Hansen RA, Carey TS. Medication error reporting in nursing homes:
identifying targets for patient safety improvement. Quality and Safety in Health Care 2010 (Epub ahead of print).
95. Roth MT, Watson LC, Esserman DA, Ivey JL, Hansen RA, Lewis CL, Weinberger M. Methodology of a
pilot study to improve the quality of medication use in older adults: enhancing quality in psychiatry using pharmacists (EQUIPP). American Journal of Geriatric Pharmacotherapy 2009; 7(6):362-72.
96. Gartlehner G, Thaler K, Hansen RA, Gaynes BN. The general and comparative efficacy and safety of duloxetine: a systematic review and meta-analysis. Drug Safety 2009; 32(12):1159-73.
97. Thaler K, Chandiramani D, Hansen RA, Gartlehner G. A systematic review and meta-analysis of the
general and comparative effectiveness and safety of anakinra. Biologics: Targets and Therapy 2009; 3:485-98.
98. Little A, Hansen RA, Gartlehner G, Gray CL. Impact of the STAR*D trial from the perspective of the
payer. Psychiatric Services 2009; 60(11):1463-65. 99. Hansen RA, Dusetzina SB, Song L, Gaynes BN, Tu W, Murray MD. Depression affects adherence
measurement but not the effectiveness of an adherence intervention in heart failure patients. Journal of the American Pharmacists Association 2009; 49(6):760-68.
100. Dorn SD, Farley JF, Hansen RA, Shah ND, Sandler RS. Direct-to-consumer and physician promotion of
tegaserod correlated with physician visits, diagnoses, and prescriptions. Gastroenterology 2009; 137(2):518-24.
101. Gartlehner G, Thieda P, Hansen RA, Morgan LC, Shumate JA, Nissman DB. Inadequate reporting of trials
compromises the applicability of systematic reviews. International Journal of Technology Assessment in Health Care 2009; 25(3):323-30.
102. Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication
adherence and classify non-adherence. Annals of Pharmacotherapy 2009; 43(3):413-22. 103. Hansen RA, Song L, Moore CG, Gilsenan AW, Kim MM, Calloway MO, Murray MD. Ropinirole effect
on sleep outcomes: meta-analysis of individual patient data from randomized controlled trials. Pharmacotherapy 2009; 29(3):255-62.
104. Hansen RA, Chin H, Blalock SJ, Joy MS. Pre-dialysis chronic kidney disease: evaluation of quality of life
in clinic patients receiving comprehensive anemia care. Research in Social and Administrative Pharmacy 2009; 5(2):143-53.
105. Hansen RA, Moore CG, Dusetzina SB, Leinwand BI, Gartlehner G, Gaynes BN. Controlling for drug dose
in systematic review and meta-analysis: A case study of the effect of antidepressant dose. Medical Decision Making 2009; 29(1):91-103.
106. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L,
Lohr KN. The comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Annals of Internal Medicine 2008; 149(10):734-50.
107. Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD. Risk of adverse gastrointestinal
events from inhaled corticosteroids. Pharmacotherapy 2008; 28(11):1325-34. 108. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, DeVeaugh-Geiss A, Krebs EE, Lohr KN. The
comparative risk for harms of second-generation antidepressants: A systematic review and meta-analysis. Drug Safety 2008; 31(10):851-65.
109. Hansen RA, Gaynes BN, Thieda P, Gartlehner G, DeVeaugh-Geiss A, Krebs EE, Lohr KN. Prevention of
major depressive disorder relapse and recurrence with second-generation antidepressants: A systematic review and meta-analysis. Psychiatric Services 2008; 59(10):1121-30.
110. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil,
galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clinical Interventions in Aging 2008; 3(2):1-15.
111. Krebs EE, Gaynes BN, Gartlehner G, Hansen RA, Thieda P, Morgan LC, DeVeaugh-Geiss A, Lohr KN.
Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and meta-analysis. Psychosomatics 2008; 23(3):191-8.
112. Hansen RA, Gaynes BN, Gartlehner G, Moore CG, Tiwari R, Lohr KN. Efficacy and tolerability of
second-generation antidepressants in social anxiety disorder. International Clinical Psychopharmacology 2008; 23(3):170-9.
113. Donahue KE, Gartlehner G, Jonas D, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Lohr KN.
Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Annals of Internal Medicine 2008; 148(2):124-34.
114. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic
arthritis: a systematic review and critical analysis of the evidence. Clinical Rheumatology 2008, 27(1):67-76.
115. Pierson S, Hansen RA, Greene S, Williams C, Akers R, Jonsson M, Carey T. Preventing Medication Errors
in Long-Term Care: Results and Evaluation of a Large Scale Web-Based Error Reporting System. Quality and Safety in Health Care 2007; 16:297-302.
116. Hansen RA, Clarke Henley A, Brouwer ES, Oraefo AN, Roth MT. Geographic information system
mapping as a tool to assess nonresponse bias in survey research. Research in Social and Administrative Pharmacy 2007; 3(3):249-64.
117. Hansen RA, Gartlehner G, Powell G, Sandler RS. Serious adverse events with infliximab: analysis of
spontaneously reported adverse events. Clinical Gastroenterology and Hepatology 2007; 5(6):729-735. 118. Fu AZ, Liu GG, Christensen DB, Hansen RA. Effect of second-generation antidepressants on mania- and
depression-related visits in adults with bipolar disorder: a retrospective study. Value in Health 2007; 10(2):128-136.
119. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer’s
disease: A systematic review and meta-analysis. Drugs and Aging 2007; 24(2):155-167.
120. Lu YJ, Farley JF, Hansen RA. Promotion and market share in the proton pump inhibitor market: a case study. Journal of Pharmaceutical Marketing and Management 2006; 17(3/4):40-59.
121. Gartlehner G, Hansen RA, Jonas B, Thieda T, Lohr KN. The comparative efficacy and safety of biologics
for the treatment of rheumatoid arthritis: A systematic review and meta-analysis. The Journal of Rheumatology. 2006;33(12):1-11.
122. Hansen RA, Roth MT, Brouwer ES, Herndon AS, Christensen DB. Medication therapy management
services in North Carolina community pharmacies: current practice patterns and projected demand. Journal of the American Pharmacists Association. 2006 Nov/Dec;46(6):700-6.
123. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool to distinguish efficacy
from effectiveness studies. Journal of Clinical Epidemiology. 2006 Oct;59(10):1040-8. 124. Shaheen NJ, Hansen RA, Gangarosa LM, Ringel Y, Morgan DR, Thiny MT, Russo MW, Sandler RS. The
burden of gastrointestinal and liver diseases, 2006. American Journal of Gastroenterology. 2006 Sep;101(9):2128-38.
125. Fu AZ, Christensen DB, Hansen RA, Liu GG. Second-Generation Antidepressant Discontinuation on
Depressive Relapse in Adult Patients with Bipolar Depression: A Retrospective Analysis. Clinical Therapeutics. 2006 Jun;28(6):979-89.
126. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients
with COPD: A systematic review and meta-analysis of health. Annals of Family Medicine. 2006 May-Jun;4(3):253-62.
127. Hansen RA, Greene SB, Williams CE, Blalock SJ, Crook KD, Akers R, Carey TS. Types of medication
errors in North Carolina nursing home errors: A target for quality improvement. American Journal of Geriatric Pharmacotherapy. 2006 Mar;4(1):52-61.
128. Trygstad TK, Hansen RA, Wegner SE. Evaluation of product switching behavior in a Medicaid population
following a policy change to cover OTC loratadine one year later than market availability. Journal of Managed Care Pharmacy. 2006; 12(2): 108-20.
129. Hansen RA, Shaheen NJ, Schommer JC. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising. Clinical Therapeutics. 2005; 27(9):1478-87.
130. Greene SB, Williams CE, Hansen RA, Crook KD, Akers R, Carey TS. Medication errors in nursing homes:
a state’s experience implementing a reporting system. Journal of Patient Safety. 2005 Dec;1(4):181-89. 131. Blalock SJ, Byrd JE, Hansen RA, Yamanis N, McMullen K, DeVellis BM, et al. Predictors of potentially
inappropriate medication drug utilization in a sample of community-dwelling older adults. American Journal of Geriatric Pharmacotherapy. 2005; 3(3): 168-79.
132. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation
antidepressants in major depressive disorder: a meta-analysis. Annals of Internal Medicine. 2005;143(6):415-26.
133. Schommer JC, Singh R, Hansen RA. Distinguishing characteristics of patients who seek more information
or request a prescription in response to direct-to-consumer advertisements. Research in Social and Administrative Pharmacy. 2005;1(2): 231-50.
134. Hansen RA, Droege M. Methodological challenges surrounding direct-to-consumer advertising research –
The measurement conundrum. Research in Social and Administrative Pharmacy. 2005;1(2): 331-47. 135. Gartlehner G, Hansen RA, Carey TS, Lohr KN, Gaynes BN, Randolph LC. Discontinuation rates for SSRIs
and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. International Journal of Psychopharmacology. 2005; 20: 59-69.
136. Schommer JC, Hansen RA. The study of direct-to-consumer advertising for prescription drugs. Research in
Social and Administrative Pharmacy. 2005;1(2): 348-68. 137. Cline RR, Farley JF, Hansen RA, Schommer JC. Osteoporosis beliefs and antiresorptive medication use.
Maturitas. 2005 Mar 14;50(3):196-208. 138. Hansen RA, Schommer JC, Cline RR, Hadsall RS, Schondelmeyer SW, Nyman JA. The association of
consumer cost-sharing and direct-to-consumer advertising with prescription drug use. Research in Social and Administrative Pharmacy. 2005;1(2): 139-57.
139. Farley JF, Cline RR, Hansen RA. Resorptive drug use among community-dwelling women in Minnesota.
Am J Health Syst Pharm. 2004 Aug 1;61(15):1577-85. 140. Schommer JC, Mott DA, Hansen RA, Cline RR. Selected characteristics of senior citizens’ prescription
drug payment and procurement in 1998 and 2001. J Managed Care Pharm. 2003; 9(5):406-15.
Peer-Reviewed Systematic Reviews and Technical Papers (most recent first) 1. Thaler KJ, Gartlehner G, Kien C, Van Noord MG, Thakurta S, Wines RCM, Hansen RA, Mcdonagh MS.
Drug class review: targeted immune modulators: Final update 3 report. March, 2012, Drug Effectiveness Review Project.
2. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux LJ, Van Noord M, Mager U, Gaynes BN, Thieda P, Strobelberger M, Lloyd S, Reichenpfader U, Lohr KN. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center, Contract
No. 290-2007-10056-I.) AHRQ Publication No. 12-EHC012-EF. Rockville, MD: Agency for Healthcare Research and Quality. December, 2011. www.effectivehealthcare.ahrq.gov/reports/final.cfm.
3. Gaynes BN, Lux L, Lloyd S, Hansen RA, Gartlehner G, Thieda P, Brode S, Swinson Evans T, Jonas D,
Crotty K, Viswanathan M, Lohr KN. Nonpharmacologic Interventions for Treatment-Resistant Depression in Adults. Comparative Effectiveness Review No. 33. (Prepared by RTI International-University of North Carolina (RTI-UNC) Evidence-based Practice Center under Contract No. 290-02-0016I.) AHRQ Publication No. 11-EHC056-EF. Rockville, MD: Agency for Healthcare Research and Quality. September 2011. www.effectivehealthcare.ahrq.gov/reports/final.cfm.
4. Donahue KE, Jonas DE, Hansen RA, Roubey R, Jonas B, Lux LJ, Gartlehner G, Harden E, Yuen A, Thieda
P, Morgan LC, Crotty K. Comparative Effectiveness of Drug Therapy for Psoriatic Arthritis in Adults - Update. Comparative Effectiveness Review No. TBD. (Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016I, TO #2.) Rockville, MD: Agency for Healthcare Research and Quality. Submitted to AHRQ for final review, September 2011.
5. Donahue KE, Jonas DE, Hansen RA, Roubey R, Jonas B, Lux LJ, Gartlehner G, Harden E, Wilkins T,
Peravali V, Bangdiwala SI, Yuen A, Thieda P, Morgan LC, Crotty K, Desai R. Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis in Adults - Update. Comparative Effectiveness Review No. TBD. (Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016I, TO #2.) Rockville, MD: Agency for Healthcare Research and Quality. Submitted to AHRQ for final review, August 2011.
6. Gartlehner G, Hansen RA, Reichenpfader U, Kaminski A, Kien C, Strobelberger M, Van Noord M, Thieda
P, Thaler K, Gaynes BN. Drug class review on second-generation antidepressants. Final peer-reviewed report; last updated March 2011, report available at http://derp.ohsu.edu/about/final-document-display.cfm
7. Gartlehner G, Thieda P, Morgan LC, Thaler K, Hansen RA, Jonas B. Drug Class Review on Targeted
Immune Modulaters: Update 2 November 2009. Final peer-reviewed report for the Drug Effectiveness Review Project. Available at http://derp.ohsu.edu/about/final-document-display.cfm
8. Gartlehner G, Morgan LC, Thieda P, Thaler K, Hansen RA, Gaynes B, Lohr KN, Carey TS. Drug class
review on second-generation antidepressants. Final peer-reviewed report; Update 4 October 2008, report available at http://www.ohsu.edu/drugeffectiveness/reports/draft.cfm
9. Gartlehner G, Hansen RA, Thieda P, DeVeaugh-Geiss AM, Gaynes BN, Krebs EE, Lux LJ, Morgan LC,
Shumate JA, Monroe LG, Lohr KN. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Comparative Effectiveness Review No. 7. (Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.) Rockville, MD: Agency for Healthcare Research and Quality. January 2007. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm
10. Gartlehner G, Thieda P, Morgan LC, Thaler K, Hansen RA, Jonas B. Drug Class Review on Targeted
Immune Modulaters: Update 1 December 2007. Final peer-reviewed report for the Drug Effectiveness Review Project. Available at http://derp.ohsu.edu/about/final-document-display.cfm
11. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas B, Hansen RA, Morgan LC, Williams
SC, Lohr KN. Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis in Adults. Comparative Effectiveness Review No. 11. (Prepared by RTI-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.) Rockville, MD: Agency for Healthcare Research and Quality. November 2007. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm
12. Gartlehner G, Jonas DE, Morgan LC, Ringel Y, Hansen RA, Bryant CM, Carey T. Drug Class Review on Constipation Drugs. Final peer-reviewed report for the Drug Effectiveness Review Project, September, 2007. Available at: http://www.ohsu.edu/drugeffectiveness/reports/documents/CONST_Final_Report_Original1.pdf
13. Gartlehner G, Hansen RA, Kahwati L, Lohr KN, Gaynes B, and Carey T. Drug class review on second-
generation antidepressants. Final peer-reviewed report available, November 2004, report available at http://www.ohsu.edu/drugeffectiveness/reports/draft.cfm
14. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. Criteria for Distinguishing Effectiveness from
Efficacy Trials in Systematic Reviews. Technical Review 12. AHRQ Publication No. 06-0046. Rockville, MD: Agency for Healthcare Research and Quality. 2006; available at http://www.ahrq.gov/downloads/pub/evidence/pdf/efftrials/efftrials.pdf
15. Gartlehner G, Hansen RA, Thieda P, Jonas B, Lohr KN, Carey TS. Drug class review on targeted immune
modulators. Final peer-reviewed report available, November 2005. Available at http://www.ohsu.edu/drugeffectiveness/reports/draft.cfm
16. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Randolph LC, and Carey T. Drug class review on
Alzheimer’s drugs. Final AHRQ-approved report available at http://www.ohsu.edu/drugeffectiveness/reports/draft.cfm; most recent update, February, 2006.
17. Hansen RA, Gartlehner G, Lohr KN, Carson S, and Carey T. Drug class review on inhaled corticosteroids.
Final AHRQ-approved report available at http://www.ohsu.edu/drugeffectiveness/reports/draft.cfm; most recent update, December, 2005.
18. Gartlehner G, Hansen RA, Kahwati L, Lohr KN, Gaynes B, and Carey T. Drug class review on second-
generation antidepressants. Final peer-reviewed report available, November 2004, report available at http://www.ohsu.edu/drugeffectiveness/reports/draft.cfm
Books and Book Chapters: 1. Hansen RA. Systematic review and meta-analysis. In: Principles of research design and drug
literature evaluation, 1st edition; RR Aparasu and JP Bentley, editors. 2014; Chapter 14:227-239. Presentations with Published Abstract or Proceedings:
1. Hastings TH, Hohmann N, Jeminiwa RN, Hansen RA, Qian J, Garza KB. Perceived Appropriateness of
Medication Adherence Incentives, Poster presentation at the AACP Annual Meeting, July 2018, Boston, Massachusetts
2. Hohmann N, Surry D, Garza KB, Hohmann L, Mishuk AU, Hansen R, Harris I, Kiptanui Z, Qian J. Improving Patient Educational Materials Regarding Generic Drugs: A Qualitative Study. Poster presentation at the 19th Annual Meeting of the American Association of Colleges of Pharmacy (AACP), Boston, Massachusetts, July 2018. American Journal of Pharmaceutical Education.
3. Hohmann N, Hastings T, Jeminiwa J, Qian J, Hansen R, Garza K. Relationship Between Perceived Medication Adherence Barriers and Incentive Preference. Poster presentation at the American Pharmacists Association (APhA) Annual Meeting, Nashville, TN, March 16-19, 2018.
4. Chou C, Hohmann NS, Hastings T, Chao L, Farley J, Maciejewski ML, Domino M, Hansen RA. Primary Care Physician, Oncologist, and Psychiatrist Comfort Levels with Prescriptions Written by Themselves and Peers for Cancer Comorbidities. Submitted to the ISPE 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE 2018). Prague, Czech Republic, August, 2018.
5. Cheng N, Hohmann N, Hastings T, Li C, Qian J, Chou CE, Hansen R. Physicians’ Perceived Awareness of Patients’ Medications: A Cross-sectional Survey. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, Baltimore, Maryland, May 2018. Value in Health.
6. Chou C, Hohmann NS, Hastings T, Chao L, Farley J, Maciejewski ML, Domino M, Hansen RA. Physicians’ comfort levels with prescriptions for cancer comorbidities that they and other healthcare providers write. Submitted to 2018 ASCO Annual Meeting. Chicago, IL, June, 2018.
7. Fahim SM, Mishuk AU, Ning C, Qian J, Calderon A, Hansen RA. Adverse Event Reporting Patterns of Concurrent Botanical Dietary Supplements with CYP3A4 Substrate & Noninteractive Anticancer Drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). American Pharmacists Association (APhA) Annual Meeting, March 16-19, 2018. Music City Center, Nashville, Tennessee.
8. Calderón, AI, Rants’o, TA, Jung, DS, McLendon, L, Qian, J, Hansen, R. LC-MS-based strategy for screening of passively absorbed açaí and maca extract constituents for CYP3A4 inhibition. The American Society of Pharmacognosy Annual Meeting. Portland, Oregon. July 29 – August 2, 2017.
9. Li, C., Hansen, R. A., Chou, C., Calderón, A. I, Qian, J. Trends in botanical dietary supplement use among US adults with cancer in NHANES 1999-2014. Poster Presentation at the American Public Health Association Annual Conference, November, 2017.
10. Hohmann N, Hastings T, Jeminiwa R, Garza KB, Qian J, Hansen R. Patient preferences for financial versus social incentives for medication adherence in chronic conditions. Oral poster presentation at the 39th Annual Meeting of the Society for Medical Decision Making (SMDM), October 22-25, 2017, Pittsburgh, PA.
11. Rahman M, Howard G, Qian J, Chou C, Hansen RA. Disparities in the appropriateness of medication use: analysis of the REGARDS study. Podium presentation at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 26-30, 2017, Montreal, Canada
12. Owensby J, Garza KB, Hansen R, Fox B, Franco-Watkins A. Leveraging behavioral economics-based interventions to improve medication adherence. Poster presentation at the American Association of Colleges of Pharmacy Annual Meeting, July 17, 2017, Nashville, TN.
13. Hastings T, Qian J, Garza KB, Hansen RA, Westrick S. Completeness of immunization information system
vaccine information: a systematic review. Podium presentation at the ISPOR 22nd International Annual Meeting, Boston, MA. May 20-24, 2017.
14. Mishuk AU, Qian J, Garza KB, Hansen RA. Impact of health insurance benefit design on generic drug use in the Unites States: a systematic review. Poster presentation at the ISPOR 22nd International Annual Meeting, Boston, MA. May 20-24, 2017.
15. Hohmann N, Garza KB, Qian J, Hansen RA. Risk of falling and fall-related injury in older adults with chronic conditions: a systematic review. Poster presentation at the ISPOR 22nd International Annual Meeting, Boston, MA. May 20-24, 2017.
16. Jeminiwa R, Qian J, Hansen RA, Garza KB, Fox B. The use of eHealth to improve medication adherence among patients with asthma: a systematic review and meta-analysis. Poster presentation at the ISPOR 22nd International Annual Meeting, Boston, MA. May 20-24, 2017.
17. Hohmann L, Qian J, Garza KB, Hansen RA, Hohmann N, Westrick S. Comparative effectiveness of opioid abuse treatments: a systematic review. Poster presentation at the ISPOR 22nd International Annual Meeting, Boston, MA. May 20-24, 2017.
18. Huo N, Qian J, Garza KB, Hansen RA. Association between asthma and risk of prostate cancer: a systematic review and meta-analysis. Poster presentation at the ISPOR 22nd International Annual Meeting, Boston, MA. May 20-24, 2017.
19. Rahman M, Alatawi Y, Cheng N, Qian J, Plotkina AV, Peissig PL, Berg RL, Page D, Hansen RA.
Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Poster presentation at the American Pharmacists Association Annual Meeting and Exposition, March 24-27, 2017, San Francisco, CA.
20. Rahman M, Alatawi Y, Cheng N, Qian J, Plotkina AV, Peissig PL, Berg RL, Page D, Hansen RA. Methodological considerations for comparison of brand versus authorized generic adverse event reports in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Poster presentation at the American Pharmacists Association Annual Meeting and Exposition, March 24-27, 2017, San Francisco, CA.
21. Alatawi Y, Rahman M, Cheng N, Qian J, Seoane-Vazquez EC, Peissig PL, Berg RL, Page D, Hansen RA. Brand versus generic adverse event reporting patterns: an authorized generic-controlled evaluation of cardiovascular medications. Poster presentation at the American Pharmacists Association Annual Meeting and Exposition, March 24-27, 2017, San Francisco, CA.
22. Cheng N, Rahman M, Alatawi Y, Qian J, Seoane-Vazquez EC, Peissig PL, Berg RL, Page D, Hansen RA. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Poster presentation at the American Pharmacists Association Annual Meeting and Exposition, March 24-27, 2017, San Francisco, CA.
23. Badger JC, LaRose E, Kleiman R, Berg R, Linneman J, Hansen RA, Page D, Peissig P. SCCS for detection of differences in brand and generic adverse drug events. Poster presentation at the American Medical Informatics Association Joint Summits, March 27-30, 2017, San Francisco, CA.
24. Gamston CE, Newton A, Hansen RA, Braxton Lloyd K. Assessment of the feasibility of utilizing employer-
based biometric screening program to prospectively recruit individuals with prediabetes into a diabetes prevention program: project in progress. Poster presentation at the Boshell Diabetes Research Day, March 4, 2017, Auburn, AL.
25. Hansen RA, Qian J, Berg RL, Linneman JG, Seoane-Vazquez E, Dutcher S, Raofi S, Page CD, Peissig P. Comparison of outcomes following a switch from a brand to an authorized vs. independent generic drug. Poster presentation at the 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), August 25-28, 2016, Dublin, Ireland.
26. Hansen RA, Qian J, Berg RL, Linneman JG, Seoane-Vazquez E, Dutcher S, Raofi S, Page CD, Peissig P. Comparison of generic-to-brand switchback patterns for authorized generic vs. independent generic drugs. Poster presentation at the 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), August 25-28, 2016, Dublin, Ireland.
27. Farley JF, Hansen RA, Domino ME, Ray N, Mahendraratnam N, Maciejewski ML. Continuity of
prescribing and medication adherence in patients with schizophrenia and cardiometabolic comorbidities.
Poster presentation at the 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), August 25-28, 2016, Dublin, Ireland.
28. Qian J, Hansen RA, Surry D, Howard J, Kiptanui Z, Harris I. Disclosure of industry payments to
prescribers: industry payments might be a factor impacting generic drug prescribing. Podium presentation at the 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), August 25-28, 2016, Dublin, Ireland.
29. Howard J, Frank G, Kiptanui Z, Qian J, Hansen RA, Harris I. Identifying who and what influences generic drug utilization in the U.S. Poster presentation at the American Public Health Association Annual Meeting, October 29 – November 2, 2016, Denver, CO.
30. Howard J, Frank G, Kiptanui Z, Qian J, Hansen RA, Harris I. Identifying and understanding who and what
influences generic drug utilization among Medicare beneficiaries. Poster presentation at the Gerontological Society of America (GSA) 2016 Annual Scientific Meeting, November 18-22, 2016, New Orleans, LA
31. Alatawi Y, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration
Adverse Event Reporting System (FAERS). Poster presentation at the American Pharmacists Association Annual Meeting and Exposition, March 4-7, 2016, Baltimore, MD.
32. Rahman M, Scalese MJ, Hansen RA. Comparative assessment of bleeding risks associated with DPP-4 inhibitors. Poster presentation that the American Pharmacists Association Annual Meeting and Exposition, March 4-7, 2016, Baltimore, MD.
33. Cheng N, Banerjee T, Qian J, Hansen RA. Association of authorized generic marketing with prescription
drug spending on antidepressants from 2000 to 2011. Podium presentation at the American Pharmacists Association Annual Meeting and Exposition, March 4-7, 2016, Baltimore, MD.
34. Hansen RA, Khodneva Y, Glasser S, Qian J, Redmond N, Safford MM. Antidepressant medication use and
its association with cardiovascular disease in the Reasons for Geographic and Ethnic Differences in Stroke (REGARDS) study. Poster accepted to the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 22-26, 2015, Boston, MA.
35. Hansen RA, Williamson M, Stevenson L, Davis BR, Evans RL. Disseminating comparative effectiveness research through community-based experiential learning in a school of pharmacy. Poster accepted to the 2015 AHRQ Research Conference co-hosted with Academy Health, October 4-6, 2015, Arlington, VA.
36. Farley JF, Hansen RA, Domino ME, Ray N, Maciejewski ML. Continuity of medication management in
Medicaid patients with chronic comorbid conditions: an examination by mental health status. Poster accepted to the 2015 AHRQ Research Conference co-hosted with Academy Health, October 4-6, 2015, Arlington, VA.
37. Garza KB, Owensby JK, Braxton-Lloyd K, Wood EA, Hansen RA. Effectiveness of different financial incentives to improve medication adherence. Poster accepted to the American Association of Colleges of Pharmacy (AACP) Annual Meeting, July 11-15, 2015, National Harbor, MD.
38. Qian J, Wittayanukorn S, Hansen RA. Patterns of psychotropic prescription utilization among disabled medicare beneficiaries under 65. Poster accepted to ISPOR 20th International Annual Meeting, May 16-20, 2015, Philadelphia, PA.
39. Sonawane KB, Qian J, Garza KB, Wright BM, Zeng P, Ganduglia Cazaban CM, Hansen RA. Patterns of treatment modifications in newly treated hypertensive patients: does choice of modification strategy affect likelihood of treatment discontinuation? Poster accepted to ISPOR 20th International Annual Meeting, May 16-20, 2015, Philadelphia, PA.
40. Wittayanukorn S, Qian J, Westrick SC, Billor N, Johnson B, Hansen RA. Risk of cardiotoxicity and all-
cause mortality in breast cancer patients after adjuvant chemotherapy or hormonal therapy. Poster accepted to ISPOR 20th International Annual Meeting, May 16-20, 2015, Philadelphia, PA.
41. Moon J, Nkurunziza J, Jambi A, Seoane-Vazquez E, Qian J, Hansen RA. Generic competition and authorized generics in the United States. Poster accepted to ISPOR 20th International Annual Meeting, May 16-20, 2015, Philadelphia, PA.
42. Sonawane KB, Hansen RA. Serious adverse drug events reported to the food and drug administration
(FDA): analysis of the fda adverse event reporting system (FAERS) 2006-2011 database. Poster accepted to ISPOR 20th International Annual Meeting, May 16-20, 2015, Philadelphia, PA.
43. Garza KB, Owensby J, Hansen R, Braxton Lloyd K. Comparison of usual care with different financial
incentives to improve medication adherence. Poster accepted to Society of Behavioral Medicine 36th Annual Meeting and Scientific Sessions, April 22, 2015, San Antonio, TX.
44. Qian J, Wittayanukorn S, McGuffey G, Gao J, Hansen RA. Psychiatric health services utilization and spending among young medicare enrollees. Poster Presentation at the American Association of Colleges of Pharmacy (AACP) 2014 Annual Meeting, July 26-30, 2014, Grapevine, TX.
45. Sonawane K, Qian J, Hansen RA. Serious adverse events reported to the Food and Drug Administration, 2006-2011. Poster Presentation at the Southern Pharmacy Administration Conference, June 20 - 22, 2014, Oklahoma City, OK.
46. Wittayanukorn S, Qian J, Hansen RA. Cardiotoxicity in targeted therapy for breast cancer: a study of the
FDA Adverse Event Reporting System (AERS). Poster Presentation at the Southern Pharmacy Administration Conference, June 20 – 22, 2014, Oklahoma City, OK.
47. Qian J, Wittayanukorn S, Gao J, Hansen RA. Trends and patterns of psychiatric prescription and emergency
department utilization among young medicare beneficiaries in 2002-2009. Poster Presentation at the AcademyHealth Annual Research Meeting (adjunct with Disability Research Interest Group Meeting), June 8-10, 2014, San Diego, CA.
48. Wittayanukorn S, Qian J, Hansen RA. Treatment patterns among breast cancer patients in the United States
2006-2010 using two national surveys on visits to physicians' offices and hospital outpatient departments. Podium Presentation at the American Pharmacists Association (APhA) Annual Meeting & Exposition, March 28-31, 2014, Orlando, FL.
49. Hansen RA. Aparasu R, West-Strum D, Hansen RA, Patel H, Zuckerman I, Rasu R, Ersin O, Shcherbakova
N. Best practices in building research teams for success in social and administrative sciences. Poster Presentation at the Annual Meeting of the American Association of Colleges of Pharmacy, July 13-17, 2013, Chicago, IL.
50. Maciejewski ML, Voils C, Powers B, Sanders L, Farley J, Sleath B, Hansen RA. Prescriber continuity and medication adherence for complex patients. Podium Presentation at the Academy Health Annual Research Meeting, June 23-15, 2013, Baltimore, MD.
51. Hansen RA, Farley JF, Maciejewski ML, Ye X, Qian C, Powers BJ. Real-world improvements in A1C with
colesevelam in an electronic medical records dataset. Poster Presentation at the Annual Meeting of the American Diabetes Association, June 21-25, 2013, Chicago, IL.
52. Wittayanukorn S, Qian J, Hansen RA. Trend and predictors of depressive symptoms and treatment in U.S. adults from 2005 to 2010. Poster Presentation at the Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 19-22, 2013, New Orleans, LA.
53. Sonawane KB, Hansen RA. Use of antihypertensive drugs in the advanced stage chronic kidney disease population in the United States. Poster Presentation at the Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 19-22, 2013, New Orleans, LA.
54. Hansen RA, Zeng P, Ryan P, Gao J, Sonawane KB, Westrich K, Dubuis RW. Exploration of heterogeneity in distributed research network drug safety analyses. Poster Presentation at the Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 19-22, 2013, New Orleans, LA.
55. Dong J, Hansen RA, Santos S, Patkowski K, Thomas E Jr., Forrest P. SPIRIT – Storing Petabytes of
Information for Research Into Tomorrow’s science. Poster presentation at Auburn University Research Week, April 1-4, 2013, Auburn, AL.
56. Hansen RA, Gray M, Fox BI, Hollingsworth J, Gao J, Zeng P. How well do various health outcome definitions identify appropriate cases in observational studies. Podium Presentation at the Annual Meeting and Exposition of the American Pharmacists Association, March 1-4, 2013, Los Angeles, CA.
57. Fox BI, Hollingsworth J, Hollingsworth M, Gray M, Carpenter MD, Hansen RA. Expert panel process for refining health outcome definitions in observational data. Poster Presentation at the Annual Meeting of the American Medical Informatics Association, November 3-7, 2012, Chicago, IL.
58. Ellis AR, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, Sturmer T. Comparison of propensity-score-weighted and –matched estimates in a comparative effectiveness study: a demonstration using STAR*D trial data. Podium presentation at the International Society for Pharmacoepidemiology (ISPE) 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 23-26, 2012, Barcelona, Spain.
59. Fox BI, Gray M, Hollingsworth J, Hollingsworth M, Gao J, Hansen RA. Developing an expert panel process for refining health definitions in observational data. Invited presentation at the 2012 Observational Medical Outcomes Partnership (OMOP) Symposium, June 28, 2012, Bethesda, MD.
60. Hansen RA, Gray M, Fox BI, Hollingsworth J, Hollingsworth M, Gao J. Expert panel review and
classification of adverse event cases identified by competing operational definitions. Invited presentation at the 2012 Observational Medical Outcomes Partnership (OMOP) Symposium, June 28, 2012, Bethesda, MD.
61. Hollingsworth J, Fox BI, Hollingsworth M, Gray M, Carpenter MD, Hansen RA. Developing an expert
panel process for refining health outcome definitions in observational data. Poster presentation at the 2012 meeting of the Southern Pharmacy Administration Conference and the Western Pharmacoeconomics Conference, June 22-24, 2012, Austin, TX.
62. Maciejewski ML, Powers BJ, Sanders L, Farley JF, Hansen RA, Sleath B, Voils CI. Implications of the
continuity of medication management for the medical home of complex patients. Podium presentation at the Academy Health 2012 Annual Research Meeting, June 24-26, 2012, Orlando, FL.
63. Desai R, Hansen RA, Williams C, Pierson S, Greene S. Medication errors during patient transition into
nursing homes: what is the impact on patients? Podium Presentation at the International Society for Pharmacoepidemiology (ISPE) 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 14-17, 2011, Chicago IL.
64. Ellis A, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, Sturmer T. Propensity scores from logistic regression yielded better covariate balance than those from a boosted model: a demonstration using STAR*D data. Podium Presentation at the International Society for Pharmacoepidemiology (ISPE) 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 14-17, 2011, Chicago IL.
65. Jones KM, Blumenthal DK, Burke JM, Condren M, Hansen RA, Holiday-Goodman M, Peterson CD.
Survey of interprofessional education in IPPEs at US colleges of pharmacy. Podium presentation at the Annual Meeting of the American Association of Colleges of Pharmacy, July 9-13, 2011, San Antonio, TX.
66. Ellis A, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, Sturmer T. Propensity scores from logistic
regression yielded better covariate balance than those from a boosted model: a demonstration using STAR*D data. Poster Presentation at the Academy Health 2011 Annual Research Meeting, June 12-14, 2011, Seattle WA.
67. Farley JF, Hansen RA, Yu-Isenberg K, Maciejewski ML. The effect of antipsychotic adherence on
adherence to diabetes, hyperlipidemia, and hypertension medications and associated health service utilization and expenditures. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research 16th Annual Meeting May 21-25, 2011, Baltimore, MD.
68. Farley JF, Hansen RA, Yu-Isenberg KS, Maciejewski ML. Trends and predictors of antipsychotic
adherence in Medicaid patients with schizophrenia: the role of comorbidity. Poster presentation at the American Psychiatric Association 2011 Annual Meeting, May 14-18, 2011, Honolulu, HI.
69. Lund J, Dusetzina SB, Gaynes BN, Pate V, Hansen RA, Jonsson Funk M. Patterns and predictors of therapy
after hospitalization for major depression. Poster presentation at the International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 19-22, 2010, Brighton, England, UK.
70. Farley JF, Hansen RA. Disruptions in antipsychotic adherence are jointly related with reduced adherence
for other chronic conditions. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research annual meeting, May 16-19, 2010, Atlanta, GA.
71. Dusetzina SB, Hansen RA, Farley JF, Weinberger M, Sleath B, Gaynes BN. Age related treatment
differences among children with bipolar spectrum disorders. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research annual meeting, May 16-19, 2010, Atlanta, GA.
72. Hansen RA, Cornell PY, Ryan PB, Williams CE, Pierson S, Greene SB. Exploring patterns in nursing home
medication errors: identification of quality improvement opportunities. Podium presentation at the American Pharmacist Association Annual Meeting, March 12-15, 2010, Washington, DC.
73. Watson L, Roth M, Lewis C, Esserman D, Hansen RA, Weinberger M. Enhancing quality in psychiatry
with pharmacists (EQUIPP) – a pilot trial. Poster presentation at the American Association of Geriatric Psychiatry Annual Meeting, March 6, 2010, Savannah, GA.
74. Dusetzina SB, Hansen RA, Pudlo A, Gaynes BN. The Feasibility of a Community Pharmacy-Based Intervention to Reduce Barriers to Antidepressant Adherence - Lessons Learned from a Pilot Study. Poster presentation at the Academy Health Annual Research Meeting, June 27- 30, 2009, Chicago, IL.
75. Dusetzina SB, Hansen RA, Song L, Gaynes, BN, Tu W, Murray MD. Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients. Poster presentation at the American Pharmacists Association (APhA) Annual Meeting & Exposition, April 3 – 6, 2009, San Antonio, TX.
76. Dusetzina, SB, Hansen, RA, Dominik, R., Gaynes, BN. Prescription Refill Records as a Screening Tool to Identify Antidepressant Non-Adherence. Podium presentation at the American Pharmacists Association (APhA) Annual Meeting & Exposition, April 3 – 6, 2009, San Antonio, TX.
77. Dorn SD, Farley JF, Hansen RA, Shah ND, Sandler RS. The effect of direct-to-consumer advertisement and
physician promotion of tegaserod (Zelnorm) on physician visits, diagnoses, and prescriptions for irritable bowel syndrome and constipation. Podium presentation at Digestive Diseases Week, June 1-4, 2009, Chicago, IL.
78. Hansen RA, Farley JF, Droege M, Maciejewski ML. A comparison of economic outcomes between
adherent and nonadherent patients treated with oral antidiabetic medications. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research annual meeting, May 16-20, 2009, Orlando, FL.
79. Greene SB, Williams C, Pierson S, Jonsson M, Akers R, Carey T, Hansen RA. Web-based Medication
Error Reporting in Nursing Homes: Opportunities to Improve Patient Safety. Poster presentation at the National Patient Safety Foundation Congress 2008, Nashville, TN.
80. Chen SY, Hansen RA, Maciejewski M. Follow-up visits for patients with major depressive disorder during
initiation of antidepressant treatment. Podium presentation at the 13th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 3-7, 2008, Toronto, ON, Canada.
81. Chen SY, Hansen RA, Maciejewski M. Effects of direct-to-consumer advertising and detail spending on
antidepressant switch and treatment continuation. Poster presentation at the 13th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 3-7, 2008, Toronto, ON, Canada.
82. Hansen RA, Moore CG, Dusetzina SB, Leinwand BI, Gartlehner G, Gaynes BN. Controlling for drug dose
in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Podium presentation at the 2008 Annual Meeting of the American Pharmacists Association, March 14-17, 2008, San Diego, CA.
83. Pudlo A, Hansen RA, Heidrick J, Ferreri S. Community pharmacy intervention to improve antidepressant
adherence. Poster presentation at the 2008 Annual Meeting of the American Pharmacists Association, March 14-17, 2008, San Diego, CA.
84. Ryan PB, Wilson MR, Hansen RA. The role of data mining in hospital discharge data for active
pharmacovigilance surveillance. Podium presentation at the 2007 Annual Meeting of the American Informatics Association, November 13, 2007, Chicago, IL.
85. Gartlehner G, Hansen RA, Thieda P, Gaynes BN, DeVeaugh-Geiss A, Krebs EE, Lohr KN. The
comparative efficacy of second-generation antidepressants for the acute-phase treatment of major depressive disorder: a systematic review and meta-analysis. Poster presentation at the 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, October 21, 2007, Dublin, Ireland.
86. Dusetzina S, Farley JF, Hansen RA. Relationship between state Medicaid copayment policies and
prescription drug utilization. Podium presentation at the Southern Pharmacy Administration Conference, June 15-17, 2007, Little Rock, AK.
87. Leinwand B, Woodard B, Hansen RA. Geographical information system mapping is a powerful tool for
identifying health care need and in pharmacy business planning. Podium presentation at the Southern Pharmacy Administration Conference, June 15-17, 2007, Little Rock, AK.
88. Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Agreement among treatment adherence measures in patients with cardiovascular disease. Poster presentation at the 2007 Annual Meeting of the American Pharmacists Association, March 16-19, 2007, Atlanta, GA.
89. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Thieda P, Carey TS. Criteria for Distinguishing
Effectiveness from Efficacy Trials in Systematic Reviews. Poster Board Presentation. The Cochrane Collaboration – North American Systematic Reviewers Conference. Baltimore, July 13-14, 2006.
90. Hansen RA, Gartlehner G, Kaufer D. Functional outcomes of drug treatment in Alzheimer’s disease: a
systematic review and meta-analysis. Podium presentation at the 2006 Annual Meeting of the American Pharmacists Association, March 17-21, 2006, San Francisco, CA.
91. Tiwari R, Hansen RA, Gartlehner G. Systematic review and meta-analysis of second-generation
antidepressant treatment outcomes in social anxiety disorder. Poster presentation at the Annual Conference of the American Society for Health System Pharmacists, December 4-8, 2005, Las Vegas, NV.
92. McAllister J IV, McAllister J III, Duda D, Hansen RA, Eckel S. Determining medication reconcilliation
adverse drug events for discharged patients at an academic medical center. Poster presentation at the Annual Conference of the American Society for Health System Pharmacists, December 4-8, 2005, Las Vegas, NV.
93. Duda D, McAllister J IV, McAllister J III, Hansen RA. Medication reconciliation during patient transfer in
and out of intensive care units in an academic medical center; collection of baseline medication variance data. Poster presentation at the Annual Conference of the American Society for Health System Pharmacists, December 4-8, 2005, Las Vegas, NV.
94. Gartlehner G, Hansen RA, Carey TS, et al. Evidence-based medicine as a decision-making tool for health
policy makers: a systematic review of second-generation antidepressants for major depressive disorder. Poster Presentation at the Annual Conference of the European Public Health Association, November 10-12, 2005, Graz, Austria
95. Gartlehner G, Hansen RA, Lohrs KN, et al. A systematic review to guide consumers’ decisions: second-
generation antidepressant for the treatment of major depressive disorder. Poster presentation at the 6th International Conference on the Scientific Basis of Health Services. September 18-20, 2005, Montreal, Canada.
96. Hansen RA, Greene SB, Williams CE, Crook KD, Akers R, Carey TS. Beers drugs and medication error
reports in North Carolina nursing homes. Poster presentation at the 21st International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 21-24, 2005, Nashville, TN
97. Gartlehner G, Hansen RA, Carey TS, Lohr KN, Gaynes BN, Randolph LC. Discontinuation rates for SSRIs
and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Poster presentation at the 21st International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 21-24, 2005, Nashville, TN
98. Greene SB, Williams CE, Hansen RA, Crook KD, Akers R, Carey TS. Medication errors in nursing homes:
a states experience implementing a reporting system. Poster presentation at the 2005 Academy Health meeting, June 26-28, 2005, Boston, MA.
99. Fu AZ, Hansen RA, Christensen DB. Effect of second-generation antidepressant discontinuation on
depressive relapse in adult patients with bipolar disorder. Podium presentation at the 2005 Annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 15-18, 2005, Crystal City, VA.
100. Hansen RA, Shaheen NJ, Schommer JC. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising. Poster presentation at the 2005 Digestive Diseases Week meeting, May 15-19, 2005, Chicago, IL
101. Trygstad TK, Hansen RA, Wegner SE. An epidemiological approach to evaluating product switching
behavior following the over-the-counter conversion of loratadine in a Medicaid population. Podium presentation at the 2005 Annual Meeting of the American Pharmacists Association, April 1-5, 2005, Orlando, FL
102. Hansen RA, Trygstad TK, and Wegner S. The effect of Medicaid coverage decisions on second-generation
antihistamine utilization and spending following over-the-counter availability of loratadine. Podium (and poster) presentation at the 2004 Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 16-19, 2004, Crystal City, VA.
103. Hansen RA, Schommer JC, and Cline RR. The effect of direct-to-consumer advertising on prescription drug
use among the insured. Podium presentation at the 2004 Annual Meeting of the American Pharmacists Association, March 26-30, 2004, Seattle, WA.
104. Hansen RA and Schommer JC. Methodological issues in evaluating the effect of localized direct-to-
consumer prescription drug advertisements: the case of the retrospective cohort study. Poster presentation at the 2003 Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October 25-29, 2003, Salt Lake City, Utah
105. Hansen RA and Schommer JC. Theories of advertising applied to direct-to-consumer advertising of
prescription drugs. Poster presentation at the 2003 Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October 25-29, 2003, Salt Lake City, Utah
106. Schommer JC, Singh R, and Hansen RA. Does advertising result in medicalizing normal human experience
or trivializing prescription drug use? Poster presentation at the 2003 Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, October 25-29, 2003, Salt Lake City, Utah
107. Hansen RA, Schommer JC, Mott DA, and Cline RR. Exploring prescription drug coverage and drug use for
older Americans – 2001. Poster presentation at the 2003 Annual Meeting of the American Pharmaceutical Association, March 28 – April 2, 2003, New Orleans, LA
108. Schommer C, Singh R, and Hansen RA. Patients’ information seeking and requests about prescription
drugs advertised in 2001-2002,” Poster presentation at the 2003 Annual Meeting of the American Pharmaceutical Association, March 28 – April 2, 2003, New Orleans, LA
Non-refereed Publications (most recent first) 1. Hansen RA, Cheng N, Rahman MM, Alatawi Y, Qian J, Peissig PL, Berg RL, Page CD. Authors' Reply to
Courtney Suggs and Colleagues' Comment on: "Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs". Drug Safety. 2018 41(12):1423-1424.
2. Gartlehner G, Gaynes BN, Hansen RA, Lohr KN. Ranking antidepressants. Lancet 2009; 373(9677):1761.
3. Gartlehner G, Hansen RA. Are some antidepressants better than others? Nature Reviews Neurology 2009; 5(5):239-40.
4. Williams CE, Greene SB, Hansen RA, Pierson S, Desai R. North Carolina Nursing Home Medication Error Quality Initiative (MEQI), Annual Report FY2012, October 1, 2011 to September 30, 2012. Chapel Hill, NC. The Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill.
5. Williams CE, Greene SB, Hansen RA, Pierson S, Akers R, Caprio A, Desai R. North Carolina Nursing Home Medication Error Quality Initiative (MEQI), Annual Report FY2011, October 1, 2010 to September 30, 2011. Chapel Hill, NC. The Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill.
6. Williams CE, Greene SB, Hansen RA, Pierson S, Akers R, Caprio A, Desai R. North Carolina Nursing Home Medication Error Quality Initiative (MEQI), Annual Report FY2010, October 1, 2009 to September 30, 2010. Chapel Hill, NC. The Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill.
7. Williams CE, Greene SB, Hansen RA, Pierson S, Akers R, Carey T. Nursing Home Medication Error Quality Initiative, MEQI Report: Year 6, October 1, 2008 to September 30, 2009. Chapel Hill, North Carolina. The Cecil G. Sheps Center for Health Services Research at the University of North Carolina.
8. Greene SB, Williams CE, Hansen RA, Akers R, Pierson S, Jonson M, Carey TS. Nursing Home Medication Error Quality Initiative (MEQI) – Year 5. Report to the North Carolina Division of Facility Services, February 2009
9. Greene SB, Williams CE, Hansen RA, Akers R, Pierson S, Jonson M, Carey TS. Nursing Home Medication Error Quality Initiative (MEQI) – Year 4. Report to the North Carolina Division of Facility Services, February 2008
10. Greene SB, Williams CE, Hansen RA, Akers R, Pierson S, Jonson M, Carey TS. Nursing Home Medication Error Quality Initiative (MEQI) – Year 3. Report to the North Carolina Division of Facility Services, February 2007
11. Greene SB, Williams CE, Hansen RA, Akers R, Pierson S, Carey TS. Nursing Home Medication Error Quality Initiative (MEQI) – Year 2. Report to the North Carolina Division of Facility Services, February 2006
12. Greene SB, Williams CE, Hansen RA, Akers R, Crook K, Carey TS. Nursing Home Medication Error Quality Initiative (MEQI) – Year 1. Report to the North Carolina Division of Facility Services, February 2005
13. Hansen RA, Schommer JC, Hadsall RS, Larson TA, Schondelmeyer SW, Uden DL. Minnesota pharmacist workforce: a pharmacy perspective. Minnesota Pharmacist. 2001; 55(4): 17-20.
14. Schommer JC, Hansen RA. A problem well defined is half solved: methodological issues related to the study of direct-to-consumer advertising (DTCA) for prescription drugs. A paper commissioned by the Department of Health Human Services, Office of the Assistant Secretary for Planning and Evaluation, Washington, DC, Final Post Conference Draft published June 18, 2001, http://aspe.hhs.gov.
Invited Presentations: 1. Hansen RA. Methodological research with drug safety surveillance systems. Invited presentation at
DUPHAT. March 7, 2017, Dubai, UAE.
2. Hansen RA. Medication adherence: measurement and the role of patient complexity. Invited presentation at DUPHAT. March 9, 2017. Dubai, UAE.
3. Hansen RA. Post-market authorized generic evaluation. Invited presentation at the FDA-sponsored symposium Substitutability of Generic Drugs: Perceptions and Reality. November 18, 2016, Silver Spring, MD.
4. Hansen RA. Data Management. Webinar found in Essentials of Practice-Based Research for Pharmacists (2016). Available at http://elearning.ashp.org/products/5427/essentials-of-practice-based-research-for-pharmacists-not-for-ce
5. Hansen RA. Advancing the science of drug safety. Auburn Talks presentation at the 2015 Auburn
University Faculty Research Symposium, September 30, 2015.
6. Hansen RA. Making good sense of good science: the value of targeted dissemination towards achieving health equity (session #26). Panelist at the 2015 AHRQ Research Conference co-hosted with Academy Health, October 4-6, 2015, Arlington, VA.
7. Hansen RA. Using data in quality improvement. Invited speaker at the Medicaid Care Network Medical Directors Meeting, February 11, 2014 .
8. Hansen RA. Pharmacy measures. Invited speaker for the Medicaid Regional Care Organizations Quality Assurance Committee meeting, January 10, 2014.
9. Hansen RA. Auburn University Initiatives in Telehealth. Invited speaker at the Telehealth and Rural Health Summit, October 17-18, 2013, Prattville, AL.
10. Hansen RA. Using research to influence policy and practice. Invited speaker at the Chapel Hill Drug Conference, May 16-17, 2013, Chapel Hill, NC.
11. Hansen RA. Perspectives on the Drug Effectiveness Review Project. Keynote address at the Fall Governance Conference of the Drug Effectiveness Review Project, October 4-6, 2011, Portland, OR.
Grants and Contracts: 6/1/19 – 5/31/22 Drug Effectiveness Review Project (Oregon Health and Science University) Comparative Effectiveness Review – master contract PI Up to $500,000 (topics individually contracted) 9/5/16 – 8/31/18 U.S. Food and Drug Administration; Grant No. 1U01FD005875-01 Generic Drug Substitution in Special Populations Co-Investigator (Qian PI) $399,990 10/1/16 – 9/30/17 Auburn University Research Initiative in Cancer (AURIC) Appropriateness and Coordination of Medication Prescribing Across Cancer Patients
Seeing Multiple Different Healthcare Providers PI $20,000
10/1/16 – 9/30/18 Auburn University Research Initiative in Cancer (AURIC) Safety Evaluation of the Concomitant Use of Botanical Dietary Supplements and
Anticancer Drugs Co-Investigator (Calderon PI) $200,000 9/1/15 – 6/30/20 National Institutes of Health; Grant No. 2R01GM097618-04 Machine Learning for Adverse Drug Events
Subcontract PI (University of Wisconsin prime – Page) $635,376 (Auburn subcontract)
9/30/15 – 9/29/20 U.S. Food and Drug Administration; Contract No. FDA BAA-13-0019 Comparative Surveillance of Generic Drugs by Machine Learning Subcontract PI (Marshfield Clinic Research Foundation prime – Peissig)
$519,736 (Auburn subcontract) 9/15/15 – 8/31/18 U.S. Food and Drug Administration; Grant No. 1U01FD005486-01 Educating Groups Influencing Generic Drug Use Co-Investigator (Qian PI) $749,837 8/18/15 – 3/31/24 National Institutes of Health – National Center for Advancing Translational Sciences Grant No. UL1TR001417 UAB Center for Clinical and Translational Research (CCTS) Auburn – Partner Network Investigator 1.45 CM (Kimberly PI) 9/10/14 – 8/31/17 U.S. Food and Drug Administration; Grant No. 1U01FD005272-02 Post-market Authorized Generic Evaluation (PAGE) PI $399,970 6/1/14 – 11/30/15 Agency for Healthcare Research and Quality; Grant No: 1R01HS023099-01 Continuity of Medication Management in Medicaid Subcontract PI (UNC prime – Farley) $65,244 (Auburn subcontract) 1/14/13 – 1/13/14 American Association of Colleges of Pharmacy Psychiatric Health Services Utilization and Spending Among Young Medicare Enrollees Mentor (Qian PI – New Investigator Award)
$11,000
2/1/13 – 1/31/14 Auburn University Intramural Grants Program Trends in Psychiatric Emergency Department Visits for Young Medicare Enrollees Mentor (Qian PI – Level 1 IGP grant) $5,000 2/1/12 – 1/31/13 Auburn University Intramural Grants Program SPIRIT – Storing Petabytes of Information for Research Into Tomorrow’s science Co-PI $150,000
4/1/12 – 3/31/13 National Pharmaceutical Council Heterogeneity of treatment effects across methods, populations, and data resources PI $102,184 6/1/11 – 6/30/12 Foundation for the National Institutes of Health Observational Medical Outcomes Partnership; Grant No. HANSE11OMOP Developing a structured process for measuring and interpreting health outcomes of
interest in the OMOP common data model PI $212,850 1/1/06 – 1/31/13 North Carolina Division of Facilities Service Medication Error Reporting in North Carolina Nursing Homes Subcontract with the Cecil G. Sheps Center for Health Services Research Co-investigator $600,000 9/30/10 – 9/29/12 Agency for Healthcare Research and Quality; Grant No. 1R21HS019445 US Department of Health and Human Services The Continuity of Medication Management (COMM) Study Subcontract PI $44,851 (subcontract total costs) 5/15/09 – 8/14/10 Agency for Healthcare Research and Quality; Contract No. 292-02-00600001I, Task Order #2, Work Assignment #3
US Department of Health and Human Services Refractory Depression, Non-Pharmacological Interventions: A Systematic Review Co-investigator $500,000
7/15/08 – 1/15/11 Agency for Healthcare Research and Quality (AHRQ) DEcIDE Network Addressing Knowledge Gaps in the Treatment of Depression Co-PI (with Bradley Gaynes) $359,780 6/15/09 – 11/7/10 Agency for Healthcare Research and Quality; Contract No. 290-02-0016, Task Order #11, Work Assignment #2-2
US Department of Health and Human Services Comparative Effectiveness of Drug Therapy for Rheumatoid and Psoriatic Arthritis in Adults: Update Co-investigator $216,478
6/15/09 – 1/14/11 Agency for Healthcare Research and Quality; Contract No. 290-02-0016, Task Order #7, Work Assignment #7-2
US Department of Health and Human Services Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacological Treatment of Adult Depression: Update UNC-PI $216,478
7/1/06 – 4/30/09 K12 Mentored Clinical Research Career Development Program; K12RR023248 US Department of Health and Human Services National Institutes of Health Co-mentors: Michael Murray, PharmD and Bradley Gaynes, MD
$530,455 8/1/07 – 7/31/08 Investments for the Future; University of North Carolina School of Medicine Enhancing Quality in Psychiatry with Pharmacists (EQUIPP) Trial Co-Investigator $140,000
1/1/07 – 6/30/07 Oregon Health Sciences University; Center for Evidence Based Policy Drug Effectiveness Project - Subcontract with the UNC-RTI Evidence-Based Practice Center and the Cecil G. Sheps Center for Health Services Research Drug Effectiveness Review on Drugs for chronic constipation
Co-investigator $4,437 5/1/06 – 2/28/07 Agency for Healthcare Research and Quality (AHRQ)
US Department of Health and Human Services Drug Effectiveness Review on Targeted Immune Modulators Co-investigator $144,607
8/1/05 – 6/19/06 Agency for Healthcare Research and Quality; Contract No. 290-02-0016, TO #7
US Department of Health and Human Services Drug Effectiveness Review on Antidepressant Medications Co-investigator $141,204
1/1/05 – 12/31/05 American Association of Colleges of Pharmacy and The American Foundation for Pharmaceutical Education New Investigators Program (NIP) grant (PI) “Predicting the switch; pharmaceutical promotion, insurance, and treatment costs” $10,000 1/1/04 – 12/31/04 University of North Carolina; Office of the Executive Vice Chancellor & Provost Junior Faculty Development Award (PI) $5,000 2/1/04 – 2/1/05 University of North Carolina School of Pharmacy/Pharmacy Foundation of North Carolina; Faculty Seed Grant Award (PI) “Economic and Clinical Outcomes Associated with Coverage of an Over-the-Counter Proton Pump Inhibitor in a North Carolina Medicaid Population” $4,500 12/1/03 – 11/30/06 Oregon Health Sciences University; Center for Evidence Based Policy Drug Effectiveness Project - Subcontract with the UNC-RTI Evidence-Based Practice Center and the Cecil G. Sheps Center for Health Services Research Scientific Director $336,000
Professional Service: To Discipline: 2014 – present Reviewer, CNS Drugs 2013 – present Alabama Regional Care Organization – Quality Assurance Committee (appointed) 2013 Communications Committee – American Pharmacists Association 2013 Delegate – American Pharmacists Association 2012 – 2013 Policy Committee – American Pharmacists Association 2011 – 2013 Chair Elect / Chair of the Academy of Pharmaceutical Research and Science - Economic,
Social, and Administrative Sciences Section of APhA 2011 – present Reviewer, Medical Care 2011 – present AACP NIA reviewer 2010 Reviewer, Medical Decision Making 2010 Reviewer, Journal of Clinical Psychopharmacology 2010 Advisory Board: Comparative Effectiveness Study Committee for the North Carolina General Assembly 2010 – present Abstract Reviewer: AACP Annual Meeting 2009 Tenure dossier review – University of Oklahoma 2009 Advisory Board: NC Quality Center Patient Safety Organization 2009 Reviewer, Journal of Affective Disorders 2009 Reviewer, BMC Public Health 2008 – 2012 Reviewer, Journal of the American Geriatric Society 2008 – present Reviewer, Annals of Internal Medicine 2008 – 2011 Abstract reviewer, ISPOR Annual Meeting 2008 Reviewer, Journal of Gerontology: Social Sciences 2007 – 2008 Delegate, American Association of Colleges of Pharmacy 2007 Reviewer, Archives of General Psychiatry 2007 Reviewer, Pharmacotherapy 2006 – 2007 Content Advisor; Eisenberg Center Comparative Effectiveness Reviews 2006 – 2013 Reviewer, Archives of Internal Medicine 2004 – present Editorial Advisory Board; Research in Social and Administrative Pharmacy 2004 – present Abstract Reviewer: APhA Annual Meeting 2004 – 2007 International Society for Pharmacoeconomics and Outcomes Research, University of
North Carolina Student Chapter, Faculty Advisor 2004 – present Reviewer; Journal of the American Pharmacists Association 2004 – present Reviewer; Research in Social and Administrative Pharmacy 2004 – present Reviewer; Journal of Managed Care Pharmacy 2004 – 2006 Advisor to state Medicaid decision-makers for Arkansas, Oregon, Idaho, and Washington
State for drugs to treat Alzheimer’s disease, COPD, and asthma 2004 – 2007 Content Advisor; Consumer’s Union comparative drug class reviews 2005 – 2008 International Society for Pharmacoepidemiology, University of North Carolina Student
Chapter, Faculty Advisor 2005 – 2006 Reviewer; Clinical Therapeutics 2005 – 2006 American Pharmacists Association 2006 Annual Meeting Planning Committee; Research
Roundtables 2004 – 2005 American Pharmacists Association; Medication Therapy Management Outcomes
Task Force 2004 Selection Committee, Medicare Discount Drug Card for Senior Care; Department of
Health and Human Services; Office of Research, Demonstrations and Rural Health Development
2004 – 2007 Reviewer; Value in Health
Within Institution 2015 – 2019 Dissertation Committee Chair, Auburn University, Md. Motiur Rahman 2015 – 2019 Dissertation Committee Chair, Auburn University, Ning Cheng 2014 – 2019 Dissertation Committee Chair, Auburn University, Yasser Alatawi 2013 Harrison School of Pharmacy Search Committee, Chief Operating Officer 2012 – 2015 Dissertation Committee Chair, Auburn University, Saranrat Wittayanukorn 2012 – 2014 Pharmacal Sciences Department Head Search Committee Chair, Auburn University
Harrison School of Pharmacy 2010 – 2017 Auburn University Harrison School of Pharmacy, Department Head, Health Outcomes
Research and Policy 2010 – 2012 Auburn University Chairs Council 2010 – present Auburn University Harrison School of Pharmacy Executive Committee 2010 – present Auburn University Harrison School of Pharmacy Strategic Planning Committee 2010 – 2017 Auburn University Harrison School of Pharmacy Health Services Board 2010 – 2017 Auburn University Harrison School of Pharmacy Clinical Services Advisory Board 2010 – 2017 Auburn University Harrison School of Pharmacy Residency Advisory Board 2010 – 2017 Auburn University Harrison School of Pharmacy Space and Facilities Committee 2010 – 2017 Auburn University Harrison School of Pharmacy Budget Advisory Committee 2010 – 2015 Dissertation Committee Chair, Auburn University, Kalyani Sonawane 2010 – 2013 Dissertation Committee, University of North Carolina School of Pharmacy; Rishi Desai 2010 – 2012 Masters Committee, Auburn University, Saranrat Wittayanukorn 2008 – 2010 Dissertation Committee Chair, University of North Carolina School of Pharmacy; Patrick Ryan 2008 – 2010 Dissertation Committee Chair, University of North Carolina School of Pharmacy; Brian Leinwand 2008 – 2010 Dissertation Committee Chair, University of North Carolina School of Pharmacy; Stacie Dusetzina 2009 - 2010 Divisional Director of Graduate Studies, UNC Eshelman School of Pharmacy 2008 Dissertation Committee, University of North Carolina School of Pharmacy;
Shih-Yin (Sharon) Chen 2008 Dissertation Committee, University of North Carolina School of Pharmacy;
Hisham Aljadhay 2007 – 2010 Nominations Committee, University of North Carolina School of Pharmacy 2007 – 2008 Advisory Ad Hoc Committee for Educational Renaissance, University of North Carolina
School of Pharmacy 2006 – 2010 Faculty Committee on Salary Policies, University of North Carolina School of Pharmacy 2006 – 2007 PharmD/PhD Program Committee, University of North Carolina School of Pharmacy 2006 Dissertation Committee, University of North Carolina School of Pharmacy;
Mark Patterson 2006 Faculty Search Committee, University of North Carolina School of Pharmacy, Division
of Pharmaceutical Outcomes and Policy 2006 Chair, IT Manager Search Committee, University of North Carolina School of Pharmacy 2006 Dissertation Committee, University of North Carolina School of Pharmacy;
Troy Trygstad 2004 – 2009 Chair, Honors Committee, University of North Carolina School of Pharmacy 2004 – 2010 Health Sciences Library Advisory Committee, University of North Carolina 2004 – 2006 Chair, Web Committee, University of North Carolina School of Pharmacy 2005 Faculty Search Committee, University of North Carolina School of Pharmacy Office of
Student Services 2005 Masters Committee, University of North Carolina School of Public Health;
Brian Leinwand 2005 Dissertation Committee, University of North Carolina School of Pharmacy;
Alex Fu
2004 – 2005 Faculty Search Committee, University of North Carolina School of Pharmacy Division of Pharmaceutical Policy & Evaluative Sciences
2003 – 2004 Curriculum Committee, University of North Carolina School of Pharmacy 2004 Professional Program Expansion Committee, University of North Carolina School of
Pharmacy
